The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR-FDA Summit Focuses on Study Design, Safety Considerations

ACR-FDA Summit Focuses on Study Design, Safety Considerations

June 21, 2022 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

2022 ACR-FDA SUMMIT—A better understanding of premarketing safety of treatments through dose exploration and controlled studies, as well as long-term safety in post-marketing studies, could assist rheumatoid arthritis (RA), psoriatic arthritis and other rheumatology programs in the future, according to Nadia Habal, MD, Division of Rheumatology and Transplant Medicine, Office of New Drugs, U.S. Food & Drug Administration (FDA).

You Might Also Like
  • PsA Trial Design Can Improve Patient Safety, Outcomes
  • FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
  • Results from Belimumab Safety Study
Also By This Author
  • State of the Art Session Reviews Lupus Causes, Potential Treatments

Dr. Habal

Dr. Habal and other experts addressed regulatory considerations for long-term safety assessment in clinical studies during the 2022 ACR-FDA Summit held virtually in May.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The availability of multiple, highly effective disease-modifying anti-rheumatic drugs that can help patients achieve remission or lower disease activity raises questions about the utility of long-term, placebo-controlled trials. Having patients receive suboptimal treatment for long time periods in studies is no longer appropriate, Dr. Habal said.

Traditional Study Design

Historically, treatments have been evaluated with short proof-of-concept and dose-ranging studies, followed by phase 3, confirmatory, controlled studies with 6- or even 12-month placebo-controlled periods. Studies have evolved to incorporate provisions for rescue when patients’ conditions devolve; they are transferred to alternative therapies or the active drug instead of placebo. These studies may be followed by long-term extension studies, which are often open-label and uncontrolled.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

This development paradigm presents challenges for the accurate assessment of long-term safety and efficacy of the investigational treatment, Dr. Habal explained.

“While randomized comparisons are generally reliable for assessment of short-term safety, a study design with rescue and crossover between treatment arms, and uncontrolled extension studies, complicates the longer term safety assessment,” she said.

Evaluating patients at later time points is important in these studies given the unique and latent toxicities of chronic immunosuppressives, including serious and opportunistic infections, tuberculosis, malignancy, cardiovascular morbidity and mortality.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The typical RA study program has included 3,000 to 4,000 patients. However, most of the treatment exposure in these programs is during the uncontrolled portion of the study, making it difficult to evaluate whether adverse events are attributable to study drugs or other factors.

Clinical programs in RA can be optimized to help address these challenges without increasing the size of the study population or the length of exposure, Dr. Habal said. For example, robust dose exploration can better inform the risk–benefit profile of a product and the doses to be studied in the larger phase 3 program. In addition, study design should address the importance of a controlled long-term assessment, such as using an active comparator that allows for meaningful interpretation of the long-term safety and efficacy of the investigational product.

Pages: 1 2 3 4 | Single Page

Filed Under: Meeting Reports, Safety Tagged With: ACR-FDA Summit, clinical trials, study design

You Might Also Like:
  • PsA Trial Design Can Improve Patient Safety, Outcomes
  • FDA Discussed 2021 Drug Warnings & Approvals at ACR Annual Meeting
  • Results from Belimumab Safety Study
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)